Physician profile
Thomas Makin
NPI 1215426499
$3,423.86
in general payments reported to CMS, 2019-2025
22 companies · $803 in 2025
The $803 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $800 · 2024: $1,821 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,399 · Consulting Fee: $13.24 · Education: $11.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,399.14 |
| Consulting Fee | $13.24 |
| Education | $11.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,025.89 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $304.11 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $266.17 | 2023-2025 | |
| Grifols USA, LLC | $258.39 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $216.12 | 2023-2025 | Takhzyro, Cuvitru, Eohilia |
| Biocryst US Sales Co., LLC | $202.45 | 2023-2024 | Orladeyo, Orladeyo |
| Csl Behring | $177.19 | 2023-2024 | Hizentra, Haegarda |
| Genentech USA, INC. | $175.45 | 2023-2025 | Xolair |
| Lilly USA, LLC | $124.46 | 2025 | Ebglyss |
| Amgen INC. | $116.09 | 2023-2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $109.65 | 2023-2024 | Dupixent |
| Pharming Healthcare, INC. | $89.83 | 2023-2024 | Ruconest |
| Novartis Pharmaceuticals Corporation | $82.98 | 2024-2025 | |
| Kaleo, INC. | $43.06 | 2024 | Auvi-Q |
| Optinose US, INC. | $42.64 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $33.37 | 2025 | |
| Blueprint Medicines Corporation | $31.21 | 2024-2025 | Ayvakit |
| Abbvie INC. | $30.85 | 2024 | |
| Phadia US INC. | $28.32 | 2024 | Immunocap |
| Octapharma USA, INC. | $26.54 | 2025 | Cutaquig |
| Inspire Medical Systems, INC. | $25.85 | 2024 | Inspire |
| Adma Biomanufacturing LLC | $13.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Makin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.